Want to see PBLS full AI Analyst Report?
PBLS Stock Chart & Stats
$35.58
-$0.58(-1.63%)
At close: 4:00 PM EDT
$35.58
-$0.58(-1.63%)
Day’s Range― - ―
52-Week Range$24.51 - $42.49
Previous Close$33.5
Volume69.93K
Average Volume (3M)784.38K
Market Cap
$4.72B
Enterprise Value$2.31K
Total Cash (Recent Filing)$1.12B
Total Debt (Recent Filing)$47.51M
Price to Earnings (P/E)―
Beta-0.27
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding121,952,030
10 Day Avg. Volume1,619,696
30 Day Avg. Volume784,377
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.75Price Target Upside17.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionLower total debt provides a modest counterweight to the company’s broader balance-sheet deterioration. Reducing borrowings can limit future interest obligations and preserve some financial flexibility, although the benefit is constrained by negative equity and substantial ongoing cash requirements.
Pre-Commercial Biotech StageThe pre-revenue profile is consistent with an early-stage biotechnology business developing toward commercialization rather than operating a mature sales model. This framing supports the possibility of future operating progression, although the pack provides no evidence that commercialization has yet been achieved.
Cash-Flow And Loss AlignmentCash losses broadly tracking reported net losses indicates that the company’s financial results are not being materially distorted by large non-cash adjustments. This gives a relatively direct view of funding needs and makes future improvement in operating performance easier to assess.
Bears Say
No RevenueA continued absence of revenue means the business currently has no product or service sales offsetting development costs. Without a commercial revenue base, operating progress depends on future product advancement and external funding, leaving the company exposed to prolonged pre-commercial losses.
Widening LossesWidening net and operating losses show that profitability deteriorated despite the company’s continuing development stage. Unless commercial revenue or cost discipline improves, the larger loss base can accelerate funding needs and make a successful transition to sustainable earnings more difficult.
Heavy Cash BurnThe increasing operating and free-cash-flow deficits indicate that the company is consuming more cash to fund its activities. Persistent heavy burn raises dependence on additional financing and can constrain strategic flexibility, particularly while revenue remains absent and losses continue to expand.
Parabilis Medicines, Inc. News
PBLS FAQ
What was Parabilis Medicines, Inc.’s price range in the past 12 months?
Parabilis Medicines, Inc. lowest stock price was $24.51 and its highest was $42.48 in the past 12 months.
What is Parabilis Medicines, Inc.’s market cap?
Parabilis Medicines, Inc.’s market cap is $4.72B.
When is Parabilis Medicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Parabilis Medicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Parabilis Medicines, Inc. overvalued?
According to Wall Street analysts Parabilis Medicines, Inc.’s price is currently Undervalued.
Does Parabilis Medicines, Inc. pay dividends?
Parabilis Medicines, Inc. does not currently pay dividends.
What is Parabilis Medicines, Inc.’s EPS estimate?
Parabilis Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Parabilis Medicines, Inc. have?
Parabilis Medicines, Inc. has 121,952,030 shares outstanding.
What happened to Parabilis Medicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Parabilis Medicines, Inc.?
Currently, no hedge funds are holding shares in PBLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Parabilis Medicines, Inc. Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Parabilis Medicines, Inc.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
PBLS Stock 12 Month Forecast
Average Price Target
$41.75
▲(17.34% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Meiragtx Holdings
―
Kodiak Sciences
―
Tarsus Pharmaceuticals
―
Ownership Overview
26.02% Insiders
65.09% Other Institutional Investors
5.28% Public Companies and
Individual Investors